In colon cancer, palmatine (0, 10, 30, 60, 90, and 120 μM) dose-dependently suppresses LPS-induced IL-8 elevation in HT-29 and SW-480 colorectal cancer cells and downregulates intestinal levels of IL-1α, IL-1β, IL-8, G-CSF, and GM-CSF in ApcMin/+ mice, ameliorating dysplasia and preventing inflammatory lesions in intestinal tissues (Ma W. K. et al., 2016). Here, CXCL8 is linked to malignant colon neoplasm.